RxDoctor Payments Data

Jyothi Rereddy, MD

Internal Medicine · Richardson, TXNPI 1831209055

Payments from drug & device makers

$1,541in general payments, 2019–2025

Across 99 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$392
  • Merck$186
  • Novo Nordisk$147
  • Boehringer Ingelheim$123
  • Amgen$122
  • Amarin Pharma, Inc.$111
  • plus $460 from 10 others

What the payments were for

  • Food & beverage$1,541100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,541 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$40,145
Medicare patients
123
Services billed
1,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate20$30,263
Bydureon BciseExenatide Microspheres19$29,269
JardianceEmpagliflozin16$25,911
FarxigaDapagliflozin Propanediol15$20,298
TrulicityDulaglutide13$18,720
OzempicSemaglutide11$16,179
Breo ElliptaFluticasone/Vilanterol12$11,801
Montelukast Sodium303$2,565
Rosuvastatin Calcium131$2,266
Atorvastatin Calcium291$2,093
Levothyroxine Sodium209$1,882
Duloxetine Hcl40$1,735
Losartan Potassium151$1,279
Omeprazole66$1,255
Metformin Hcl156$1,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$186$30,26320 claims
Boehringer IngelheimJardiance$123$25,91116 claims
AstraZenecaFarxiga$392$20,29815 claims
Lilly USA, LLCTrulicity$11$18,72013 claims
Novo NordiskOzempic$147$16,17911 claims
GSKBreo Ellipta$80$11,80112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Richardson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →